Business UpdateMay 28, 2026, 05:07 PM
Pelthos Therapeutics CEO to Present at Jefferies Conference
AI Summary
Pelthos Therapeutics Inc. announced that its CEO, Scott Plesha, will present and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York. The biopharmaceutical company focuses on commercializing innovative therapeutic products for unmet patient needs, including its lead product ZELSUVMI for molluscum contagiosum, and recently acquired XEPI for impetigo and XEGLYZE for head lice. The company aims to leverage its existing commercial infrastructure for these new product launches.
Key Highlights
- Pelthos Therapeutics CEO Scott Plesha to present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026.
- CEO Plesha will also participate in one-on-one investor meetings at the conference.
- Pelthos Therapeutics is a biopharmaceutical company focused on cutaneous infectious disease products.
- The company's lead product, ZELSUVMI (berdazimer) topical gel, treats molluscum contagiosum.
- Pelthos' portfolio includes XEPI (ozenoxacin) Cream for impetigo and XEGLYZE (abametapir) for head lice.
- Zelsuvmi launched in July 2025, with over 20,000 units dispensed through April 2026.
- The company reported $32.0M cash at the end of Q1 2026 and a market cap of ~$240M as of May 11, 2026.
Price Impact
More from PTHS